Frankfurt
06.12.24 | 08:01
0,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CYXONE Aktie jetzt für 0€ handeln | |||||
| 27.12.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.12.2024 | 1.436 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.12.2024ISIN NameCA33812R1091 FISSION... ► Artikel lesen | |
| 16.12.24 | Nasdaq Stockholm AB: Delisting of Cyxone AB from Nasdaq First North Growth Market | 283 | GlobeNewswire | On December 9, 2024, Cyxone AB was declared bankrupt by Malmö District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial... ► Artikel lesen | |
| 06.12.24 | XFRA 4CX: AUSSETZUNG/SUSPENSION | 307 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCYXONE AB SK-,75... ► Artikel lesen |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,872 | -1,58 % | Valneva-Aktie sorgt für Bewegung - Investoren achten auf jedes Signal!!! | ||
| NOVAVAX | 6,117 | +0,72 % | NOVAVAX INC steht still - ich rieche gewaltige Bewegung! | ||
| COSCIENS BIOPHARMA | 1,900 | -1,55 % | COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS voluntarily delists from Nasdaq, while retaining the Company's listing on the TSX COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs. Q3... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,350 | -4,93 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in... ► Artikel lesen | |
| ARGENX | 774,40 | +0,73 % | Argenx Gains Health Canada Approval For Vyvgart SC As Monotherapy In CIDP | WASHINGTON (dpa-AFX) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients... ► Artikel lesen | |
| ORAGENICS | 0,128 | 0,00 % | ORAGENICS INC - 8-K, Current Report | ||
| LEXICON PHARMACEUTICALS | 1,144 | -7,29 % | Lexicon Pharmaceuticals, Inc.: Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions ... | THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 1,343 | +6,59 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD | Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,665 | +10,83 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - ACAAI 2025 | CS2015 (OX40L/TSLP BISPECIFIC ANTIBODY) MAKES INTERNATIONAL DEBUT | ||
| SERES THERAPEUTICS | 14,120 | +3,98 % | Seres Therapeutics, Inc.: Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 | CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 1,868 | +4,10 % | GENSCRIPT BIO (01548): VOLUNTARY ANNOUNCEMENT: FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2025 OF A LISTED ASSOCIATE - LEGEND BIOTECH ... | ||
| KRYSTAL BIOTECH | 178,00 | +2,80 % | XFRA 4KB: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 5,500 | +5,77 % | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| Q32 BIO | 1,860 | -9,71 % | Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected... ► Artikel lesen | |
| XENETIC BIOSCIENCES | 2,540 | -4,51 % | Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results | Continued execution on collaborations and exploratory investigator-initiated studies with institutional partnersSecured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM... ► Artikel lesen |
Das Unternehmen CYXONE AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.